AlphaQuest LLC Buys 6,582 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

AlphaQuest LLC increased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 17.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,916 shares of the biopharmaceutical company’s stock after purchasing an additional 6,582 shares during the quarter. AlphaQuest LLC’s holdings in Catalyst Pharmaceuticals were worth $917,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of CPRX. abrdn plc bought a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth about $10,115,000. Raymond James Financial Inc. bought a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth about $6,887,000. Jane Street Group LLC grew its stake in shares of Catalyst Pharmaceuticals by 245.4% in the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after purchasing an additional 285,564 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of Catalyst Pharmaceuticals in the third quarter worth about $4,936,000. Finally, Pacer Advisors Inc. grew its stake in shares of Catalyst Pharmaceuticals by 5.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after purchasing an additional 151,495 shares during the last quarter. 79.22% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Truist Financial raised their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Stephens restated an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Finally, Robert W. Baird raised their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $32.50.

Catalyst Pharmaceuticals Trading Down 5.9 %

CPRX stock opened at $20.67 on Tuesday. The stock has a market capitalization of $2.51 billion, a PE ratio of 17.52, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.47 and a 12-month high of $24.64. The stock’s 50 day simple moving average is $22.28 and its 200 day simple moving average is $21.52.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.